NCT03719729View on ClinicalTrials.gov

Rifaximin to Modify the Disease Course in Sickle Cell Disease

PHASE2UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 22, 2018

Primary Completion Date

February 22, 2020

Study Completion Date

July 22, 2020

Conditions
Sickle Cell DiseaseAntibiotics
Interventions
DRUG

Rifaximin

Administer daily rifaximin to modify intestinal microbiome to alter the course of the disease.

Trial Locations (1)

10532

RECRUITING

Westchester Medical Cancer Cancer Institute, Valhalla

Sponsors
All Listed Sponsors
lead

New York Medical College

OTHER